Compare Cigna Corp (CI) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: Cigna Corp pays a 2.24% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Cigna Corp nearer its low. Which is the better fit depends on your goals.
| CI | FLRN | |
|---|---|---|
Market Cap | $73.56B | — |
Sector | Health | Sector/Thematic |
52-Week High | $311.00 | $30.86 |
52-Week Low | $244.41 | $30.65 |
Enterprise Value | $98.27B | — |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
FLRN trades at $30.76 with minimal daily movement (+0.03%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data. Recent dividend payments of $0.11 suggest stable income distribution, but fundamental analysis is limited without updated financial statements.
Outlook remains cautious due to bearish technical signals and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to assess profitability and growth. Primary risks include market volatility and reliance on future earnings reports for valuation clarity. Investors should await Q2 2026 results for deeper insight.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
